LINC01106 is upregulated in lung adenocarcinoma, non-small cell lung cancer, and bladder cancer (73–75) and functions as a novel diagnostic and prognostic marker in colorectal and gastric adenocarcinomas (76, 77). Here, LINC01106 is linked to urinary bladder carcinoma.